Clinical Trial Update: Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing anagrelide retard to placebo in at-risk patients with essential thrombocythemia reports efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• Anagrelide Retard (anagrelide)

Snippet

Sponsor: AOP Orphan Pharmaceuticals AG | Conditions: Essential Thrombocythaemia | Phase 3 | Status: COMPLETED